MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Zai Lab Ltd ADR

Cerrado

SectorSanidad

31.74 -13.35

Resumen

Variación precio

24h

Actual

Mínimo

31.18

Máximo

36.63

Métricas clave

By Trading Economics

Ingresos

-40M

-82M

Ventas

6.8M

109M

BPA

-0.8

Margen de beneficios

-74.891

Empleados

1,869

EBITDA

-40M

-78M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+47.26% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

445M

4.1B

Apertura anterior

45.09

Cierre anterior

31.74

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

167 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Zai Lab Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 abr 2025, 22:38 UTC

Acciones populares

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 abr 2025, 21:53 UTC

Charlas de Mercado

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 abr 2025, 21:44 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 abr 2025, 21:00 UTC

Principales Noticias

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 abr 2025, 20:52 UTC

Charlas de Mercado

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 abr 2025, 20:52 UTC

Principales Noticias

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 abr 2025, 20:48 UTC

Principales Noticias

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 abr 2025, 20:45 UTC

Principales Noticias

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 abr 2025, 20:32 UTC

Principales Noticias

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 abr 2025, 20:21 UTC

Principales Noticias

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 abr 2025, 20:00 UTC

Principales Noticias

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 abr 2025, 19:51 UTC

Charlas de Mercado

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 abr 2025, 19:37 UTC

Principales Noticias

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 abr 2025, 19:32 UTC

Charlas de Mercado

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 abr 2025, 19:28 UTC

Principales Noticias

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 abr 2025, 19:15 UTC

Charlas de Mercado

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 abr 2025, 19:12 UTC

Principales Noticias

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 abr 2025, 19:11 UTC

Charlas de Mercado

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 abr 2025, 19:09 UTC

Charlas de Mercado

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 abr 2025, 19:09 UTC

Principales Noticias

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 abr 2025, 19:00 UTC

Charlas de Mercado

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 abr 2025, 18:53 UTC

Charlas de Mercado

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 abr 2025, 18:51 UTC

Charlas de Mercado

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 abr 2025, 18:44 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 abr 2025, 18:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 abr 2025, 18:44 UTC

Charlas de Mercado

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 abr 2025, 18:43 UTC

Adquisiciones, fusiones, absorciones

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 abr 2025, 18:43 UTC

Adquisiciones, fusiones, absorciones

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 abr 2025, 18:39 UTC

Charlas de Mercado

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Comparación entre iguales

Cambio de precio

Zai Lab Ltd ADR previsión

Precio Objetivo

By TipRanks

47.26% repunte

Estimación a 12 Meses

Media 54.03 USD  47.26%

Máximo 74 USD

Mínimo 36.1 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zai Lab Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

4

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

35.09 / 37.2Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

167 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.